Form 8-K - Current report:
SEC Accession No. 0001213900-25-032947
Filing Date
2025-04-17
Accepted
2025-04-17 16:01:40
Documents
16
Period of Report
2025-04-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea023875601-8k_aldey.htm   iXBRL 8-K 27385
2 ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED APRIL 17, 2025 ea023875601ex99-1_aldey.htm EX-99.1 13381
3 GRAPHIC image_001.jpg GRAPHIC 3779
4 GRAPHIC image_002.jpg GRAPHIC 2971
  Complete submission text file 0001213900-25-032947.txt   234945

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE aldx-20250417.xsd EX-101.SCH 3047
6 XBRL LABEL FILE aldx-20250417_lab.xml EX-101.LAB 34915
7 XBRL PRESENTATION FILE aldx-20250417_pre.xml EX-101.PRE 22810
18 EXTRACTED XBRL INSTANCE DOCUMENT ea023875601-8k_aldey_htm.xml XML 3854
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 25847189
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)